Author: Leah Kosyakovsky

BrigHTN: Baxdrostat, an aldosterone synthase inhibitor,  showed dose-related reductions in blood pressure and safely and effectively lowers blood pressure in patients with resistant hypertension
AHA 2022, Hypertension, News

BrigHTN: Baxdrostat, an aldosterone synthase inhibitor, showed dose-related reductions in blood pressure and safely and effectively lowers blood pressure in patients with resistant hypertension

Key Points In a Phase 2 randomized trial, baxdrostat, a highly potent and selective aldosterone synthase inhibitor, had dose-related reductions in blood pressurein... Read more.
AHA 2022, Cardiovascular Prevention, Hypertension, News

FRESH –First-in-Class Aminopeptidase-A Inhibitor Firibastat Fails in Resistant Hypertension

Key Points Hypertension remains a major public health threat contributing significantly to rates of ischemic heart disease and strokes worldwide despite a wide array... Read more.
PRECISION –Dual Endothelin Receptor Antagonist Aprocitentan Superior to Placebo in Resistant Hypertension
AHA 2022, Hypertension, News

PRECISION –Dual Endothelin Receptor Antagonist Aprocitentan Superior to Placebo in Resistant Hypertension

Key Points Despite the many drug classes available to treat hypertension, the prevalence of resistant hypertension (hypertension requiring at least 3 blood pressure... Read more.
NOVA – No significant difference in rate of post-op AF with botulinum toxin vs placebo
AHA 2022, Arrhythmia and Electrophysiology, Atrial Fibrillation, News

NOVA – No significant difference in rate of post-op AF with botulinum toxin vs placebo

Key Points: -In a Phase II, dose-ranging trial of epicardial fat pad injection of botulinum toxin type A (AGN-151607) there was no significant differences in the... Read more.
RIVARAD: Post-Procedural Rivaroxaban Use After Radial Access for Coronary Procedures Reduces Radial Artery Occlusion at 30 Days
Interventional Cardiology, News, TCT 2022

RIVARAD: Post-Procedural Rivaroxaban Use After Radial Access for Coronary Procedures Reduces Radial Artery Occlusion at 30 Days

Key Points: Radial artery occlusion (RAO) is the most common complication after radial access for coronary procedures; while routine intra-procedural heparin administration... Read more.
EPIC-STEMI: Early Routine PCSK-9 Use Added to High Intensity Statin Reduces LDL after Primary PCI for STEMI
Acute Coronary Syndrome, Atherosclerotic Cardiovascular Disease, Cardiovascular Prevention, Coronary Artery Disease, Lipid Lowering Therapy, Myocardial Infarction, News, Statins, TCT 2022

EPIC-STEMI: Early Routine PCSK-9 Use Added to High Intensity Statin Reduces LDL after Primary PCI for STEMI

Key Points: Early high-intensity statin therapy is standard of practice in acute STEMI patients, but this is often insufficient to achieve LDL targets. PCSK-9 therapy... Read more.
Extended outcomes of BEST: No difference in MACE between PCI and CABG in MVD at 12 years, but higher repeat revascularization and spontaneous MI in PCI arm
Atherosclerotic Cardiovascular Disease, CABG, Coronary Artery Disease, News, TCT 2022

Extended outcomes of BEST: No difference in MACE between PCI and CABG in MVD at 12 years, but higher repeat revascularization and spontaneous MI in PCI arm

Key Points: Previous studies have demonstrated the superiority of CABG over PCI in the treatment of multivessel disease; however, most studies were performed without... Read more.
FLASH: The FlowTriever system has an excellent safety profile in the treatment of pulmonary embolism
News, TCT 2022, Vascular Medicine

FLASH: The FlowTriever system has an excellent safety profile in the treatment of pulmonary embolism

Key Points: Mortality for acute PE remains high. While percutaneous mechanical thrombectomy has been used in patients with hemodynamic instability, safety and effectiveness... Read more.